Avelox,Cipro and Levaquin (Antibiotics)
Legal Options
The Food and Drug Administration (FDA) mandated a stricter peripheral neuropathy (nerve damage) warning on fluoroquinolone antibiotics like Levaquin, Cipro, and Avelox on August 14, 2013. This additional warning opened the door for lawsuits against the makers of these drugs for product liability, failure to warn, negligence, and other causes of action.
Users of the popular class of antibiotics known as fluoroquinolones may face an increased risk of permanent and irreversible nerve damage, known as peripheral neuropathy. Lawsuits for users of Levaquin, Cipro, Avelox and other similar antibiotics are being reviewed by lawyers nationwide.
Levaquin, Cipro and Avelox are antibiotics known as fluoroquinolones used to treat bacterial infections of the skin, sinuses, kidneys, bladder, or prostate. They are also used to treat bacterial infections that cause bronchitis or pneumonia, and to treat people who have been exposed to anthrax.
It will speed up the process if you have the following information available before you contact us:
Our firm works on a contingency basis which means you will not be asked to pay any money out of pocket.
This process will be very easy. Please feel free to answer all questions honestly as your information is confidential.
This process will be very easy. Please feel free to answer all questions honestly as your information is confidential.
Symptoms of peripheral neuropathy from antibiotics like Levaquin, Cipro, Avelox and others may include:
FDA PERIPHERAL NEUROPATHY WARNINGS: In August 2013, the FDA announced that new and stronger warnings would be added to Levaquin, Cipro, Avelox and other fluoroquinolone antibiotics. The new warnings remove prior claims that the nerve damage cases were rare, and indicate that the problems may affect users for years after they stop taking the drug. In many cases the peripheral neuropathy causes permanent disability and limitations for the remainder of the users life. The FDA now requires that doctors be informed that any patients who experience symptoms of peripheral neuropathy on the antibiotics should stop treatment and be switched to another medication. Patients are now provided with clearer warnings indicating that it is important that they seek immediate medical treatment if they begin to see signs of peripheral neuropathy.